Study of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positive

NCT03992170 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Myeloma Multiple

Interventions

DRUG: Daratumumab

Sponsor

Azienda Ospedaliera Universitaria Senese

Collaborators

[object Object]